The impact of lymphocytosis and CD4/CD8 ratio on the anti-JCV antibody index and clinical data in patients treated with natalizumab.

Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Jan KolcavaPavel Stourac

Abstract

Natalizumab is an effective therapy in the treatment of relapsing-remitting multiple sclerosis; it induces lymphocytosis (NIL, natalizumab-induced lymphocytosis) and changes the peripheral lymphocyte pattern. This study aims to evaluate NIL, peripheral blood lymphocyte subsets, CD4/CD8 ratio, and their impacts on JCV index and clinical data-No Evidence of Disease Activity (NEDA-3) and annualized relapse rate (ARR) in patients treated with natalizumab. Forty-one patients (33 women) were included in the study. The mean duration of follow-up on natalizumab treatment was 6.7 ± 3.2 years. Significant increases in relative lymphocytosis after 1 month, with a median of 40.4% (- 34.1 to + 145.5%) (p < 0.001), and after 1 year (49.0% (- 9.3 to + 127.6%)) (p < 0.001) were found. Significant differences were found after 1 month when comparing NIL between patients JCV-seroconverting (20.6% (- 17.7 to 72.7%)) and stable JCV-seronegative ones (43.5% (- 6.3 to +96.3%)) (p = 0.04). No significant difference NIL level was found between the patients exhibiting NEDA-3 status and those without it. ARR on natalizumab treatment correlated with CD4/CD8 ratio (r = 0.356; p = 0.021); patients who maintained NEDA-3 status over the whole treatment period...Continue Reading

References

Apr 25, 2006·Annals of Neurology·Olaf StüveMichael K Racke
Dec 14, 2007·Neuro-degenerative Diseases·Britta Engelhardt, Ludwig Kappos
Jul 2, 2009·Expert Opinion on Biological Therapy·Frank NeumannRainer Haas
Jun 15, 2010·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·F SangalliG Comi
Aug 26, 2010·Annals of Neurology·Leonid GorelikMeena Subramanyam
Dec 24, 2010·Multiple Sclerosis : Clinical and Laboratory Research·Giovanni FrisulloAnna Paola Batocchi
May 18, 2012·The New England Journal of Medicine·Gary BloomgrenCarmen Bozic
Mar 6, 2013·Multiple Sclerosis : Clinical and Laboratory Research·Tomas OlssonDorothea Buck
Mar 8, 2013·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Peter LeeMeena Subramanyam
Sep 28, 2013·Multiple Sclerosis : Clinical and Laboratory Research·Olivier OutteryckPatrick Vermersch
Jan 7, 2014·Clinical and Experimental Immunology·T KoudriavtsevaP Cordiali-Fei
Feb 18, 2014·Journal of Neurology, Neurosurgery, and Psychiatry·Helmut ButzkuevenUNKNOWN TYSABRI Observational Program (TOP) Investigators
Oct 24, 2014·Neurology. Neuroimmunology and Neuroinflammation·Ilya KisterJoseph Herbert
Nov 14, 2014·Multiple Sclerosis : Clinical and Laboratory Research·Clemens WarnkeBernd C Kieseier
Sep 9, 2015·Acta Neurologica Scandinavica·M KolasaI Elovaara
Oct 11, 2015·Multiple Sclerosis : Clinical and Laboratory Research·E SignorielloG Lus
Mar 29, 2016·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A VennegoorJ Killestein
May 22, 2016·Journal of the Neurological Sciences·Yolanda AladroJose Meca-Lallana
Jun 12, 2017·Journal of Neuroimmunology·Antonio CarotenutoRoberta Lanzillo
Dec 26, 2017·Lancet Neurology·Alan J ThompsonJeffrey A Cohen
Nov 6, 2018·Therapeutic Advances in Neurological Disorders·Marco PuthenparampilPaolo Gallo
Apr 6, 2019·Frontiers in Immunology·Alessandro CamponeschiOla Grimsholm

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Nihon rinsho. Japanese journal of clinical medicine
Masaya HondaTakashi Kanda
Revue de l'infirmière
Corinne Taéron
Nature Reviews. Drug Discovery
John H Noseworthy, Peter Kirkpatrick
© 2021 Meta ULC. All rights reserved